ReportGem ReportGem

U.S. COMPANY FILING

ALNYLAM PHARMACEUTICALS, INC. — Form 8-K filed 2026-04-30

Filed: 2026-04-30Company: ALNYLAM PHARMACEUTICALS, INC.Ticker: ALNYExchange: NasdaqForm: 8-KReport period: 2026-04-30SEC accession: 0001628280-26-028601Event: earningsMateriality: 70

Filing text preview

Alnylam Pharmaceuticals announced its Q1 2026 financial results on April 30, 2026, with the press release furnished as Exhibit 99.1. The company noted that the information is furnished, not filed, and thus not subject to Section 18 liabilities. Specific financial figures were not disclosed in the 8-K.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-04-3010-Q2026-07-30 · 10-Q8-K2026-07-30 · 8-K10-Q2026-04-30 · 10-Q10-K2026-02-12 · 10-K8-K2026-02-12 · 8-K8-K2026-01-12 · 8-K